4CPS-110 Impact of patients’ conditions on the effectiveness and safety of erlotinib in pancreatic cancer

BACKGROUND: In post-PA studies in the use of erlotoinib, it was observed that the favourable clinical situation benefited the response to treatment. PURPOSE: To compare the effectiveness and safety of erlotinib, according to the Eastern Cooperative Oncology Group (ECOG), in pancreatic cancer. MATERI...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Eur J Hosp Pharm
Main Authors: García, I Muñoz, Martínez-Penella, M, Mira-Sirvent, MC, Núñez-Bracamonte, S, Conesa-Nicolás, E, Viney, AC, Juez-Santamaria, C, Lloret-Llorca, A, García-Márquez, A, García-Lagunar, MH, Gutiérrez-Cívicos, MDR
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Group 2018
Assuntos:
Section 4: Clinical pharmacy services
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7535307/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.201
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados